Vaccination against diabetes, obesity and complications thereof
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Universite Paul Sabatier Toulouse III, Centre Hospitalier Universitaire De Toulouse
InventorsVincent Blasco-Baque, Lucile Garidou, Rémy Burcelin
Life of this patent
Estimating the term…
Abstract
Vaccines for preventing or treating diabetes, obesity and complications thereof are provided. The vaccines comprise at least one active agent such as attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a cDNA from Porphyromonas gingivalis.
Claims10
A method for preventing or treating diabetes in a subject in need thereof, comprising
- administering a prophylactically or therapeutically effective amount of a vaccine composition comprising:
- at least one prophylactically or therapeutically active agent selected from the group consisting of attenuated Porphyromonas gingivalis and inactivated Porphyromonas gingivalis, and
- at least one additional prophylactically or therapeutically active agent selected from the group consisting of live attenuated Fusobacterium nucleatum and killed or inactivated Fusobacterium nucleatum and/or at least one additional prophylactically or therapeutically active agent selected from the group consisting of live attenuated Prevotella intermedia and killed or inactivated Prevotella intermedia.
A method for preventing or treating insulinemia and/or glucose-intolerance in a subject in need thereof, comprising
- administering a prophylactically or therapeutically effective amount of a vaccine composition comprising
- at least one prophylactically or therapeutically active agent selected from the group consisting of attenuated Porphyromonas gingivalis and inactivated Porphyromonas gingivalis, and
- at least one additional prophylactically or therapeutically active agent selected from the group consisting of live attenuated Fusobacterium nucleatum and killed or inactivated Fusobacterium nucleatum and/or at least one additional prophylactically or therapeutically active agent selected from the group consisting of live attenuated Prevotella intermedia and killed or inactivated Prevotella intermedia.
Dependencies are inferred from the claim text.